logo

For the Inventor, By the Inventor

Chalfont, PA, United States of America

John D Prugh

This inventor holds 23 USPTO granted patents, primarily in Pharmaceutical Compounds. Top assignee: Merck + Co., Inc.. Active years: 1976-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John D Prugh. Retrieved from https://idiyas.com/inventor/john-d-prugh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23

% Patents Active = 100.0

Average Co-Inventor Count = 1.5

ph-index = 7

Forward Citations = 148(Granted Patents)


Location History:

  • Lansdale, PA (US) (1976)
  • Chalfond, PA (US) (1990)
  • Chalfont, PA (US) (1976 - 1998)

Company Filing History:

goldMedal23 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1976-1998

Loading Chart...
Areas of Expertise:
Fibrinogen Receptor Antagonists
HMG-CoA Reductase Inhibitors
Antiglaucoma Agents
Thieno Compounds
Gastric Acid Suppression
Pyrimidylcarbamates
Synthetic Analogs
Heterocyclic Carbamates
Appetite Stimulants
Cyano Derivatives
23 patents (USPTO):Explore Patents
1. 5786373 - Fibrinogen receptor antagonists (1998-07-28),
2. 5559127 - Fibrinogen receptor antagonists (1996-09-24),
3. 5397791 - Fibrinogen receptor antagonists (1995-03-14),
4. 5334596 - Fibrinogen receptor antagonists (1994-08-02),
5. 4946864 - Novel HMG-CoA reductase inhibitors (1990-08-07),
6. 4929549 - 5-carbamoylthieno[2,3-b]thiophene-2-sulfon-amides as topically active (1990-05-29),
7. 4894390 - Substituted thieno[2,3-b]thiophene-2-sulfonamides as antiglaucoma agents (1990-01-16),
8. 4876271 - Substituted thieno[3,2-b]thiophene-2-sulfonamides as topically active (1989-10-24),
9. 4806562 - Substituted thieno[2,3-b]thiophene-2-sulfonamides as antiglaucoma agents (1989-02-21),
10. 4798831 - Substituted thieno[2,3-B]furan-2-sulfonamides as antiglaucoma agents (1989-01-17),
11. 4683314 - 3-O-benzyl-2,4,6-tridooxy-6-iodo-alpha-D-erythro-hexopyranide useful for (1987-07-28),
12. 4654363 - Synthetic analogs of mevinolin (1987-03-31),
13. 4540796 - Process for preparing inhibitors of 3-hydroxy-3-methylglutaryl coenzyme (1985-09-10),
14. 4440927 - Process for preparing inhibitors of 3-hydroxy-3-methylglutaryl coenzyme (1984-04-03),
15. 4415575 - Suppression of gastric acid secretion using pyrimidylcarbamates (1983-11-15),

Title: John D Prugh: Innovator in Fibrinogen Receptor Antagonists

Introduction: John D Prugh, based in Chalfont, PA, has made a significant impact in the field of pharmaceuticals, holding a remarkable 23 patents. His work, particularly in the study and development of fibrinogen receptor antagonists, continues to shape medical research and treatment possibilities.

Latest Patents: Among his latest innovations are the fibrinogen receptor antagonists, which are crucial in developing treatments for various medical conditions. These patents exemplify his commitment to advancing medical science and showcase his innovative spirit.

Career Highlights: John D Prugh's career is marked by his association with Merck & Company, Inc., where he has collaborated extensively with leading professionals in the field. His contributions to the pharmaceutical industry have earned him recognition as a forward-thinking inventor.

Collaborations: Throughout his career, John has collaborated with esteemed colleagues, including George D Hartman and Wasyl Halczenko. These partnerships have been instrumental in refining his innovations and expanding the scope of his research initiatives.

Conclusion: John D Prugh represents the essence of innovation in the pharmaceutical industry, with a noteworthy patent portfolio and impactful collaborations. His work on fibrinogen receptor antagonists reflects a commitment to improving healthcare outcomes, solidifying his place as a significant contributor to medical advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…